Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Lilly boosts R&D work in Singapore
April 2007
SHARING OPTIONS:

SINGAPORE—U.S. pharmaceutical giant Eli Lilly is expanding its drug discovery efforts in Singapore, spending $150 million to extend its research and development facility there over five years. The primary goal of this expanded R&D is to develop new drugs for cancer and diabetes. The new research facility reportedly will be the largest corporate R&D centre in Singapore.
 
Eli Lilly's current facility at Science Park II will be renamed the Lilly-Singapore Centre for Drug Discovery, to reflect its new partnership with the Economic Development Board there. The new facility will triple the size of Eli Lilly's operations in Singapore to 150 research scientists and is expected to build on the company's strength in computational cancer research.
 
Indianapolis-based Eli Lilly said the expansion was in part an efforts to be closer to Asia, a key, growing market. Asia currently accounts for less than a fifth of Lilly's total sales.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.